Form 8-K - Current report:
SEC Accession No. 0000950170-25-025640
Filing Date
2025-02-24
Accepted
2025-02-24 16:16:55
Documents
12
Period of Report
2025-02-24
Items
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K kpti-20250224.htm   iXBRL 8-K 58907
2 EX-3.1 kpti-ex3_1.htm EX-3.1 18194
  Complete submission text file 0000950170-25-025640.txt   206557

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT kpti-20250224.xsd EX-101.SCH 31871
14 EXTRACTED XBRL INSTANCE DOCUMENT kpti-20250224_htm.xml XML 4881
Mailing Address 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459
Business Address 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459 617-658-0600
Karyopharm Therapeutics Inc. (Filer) CIK: 0001503802 (see all company filings)

EIN.: 263931704 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36167 | Film No.: 25657216
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)